Allakos Inc. ALLK
0.33 0.00 (+0.00%)
At closeMay 15, 2025, 4:00 PM EDT
0.3291 Day range 0.3291
52-week range unavailable
- YTD
- -72.80%
- 1 year
- -72.34%
News
prnewswire.com $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK NEW YORK , April 2, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
businesswire.com ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Allakos Inc. (NASDAQ: ALLK) to Concentra Biosciences, LLC for $0.33 in cash per share is…
businesswire.com Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to…
globenewswire.com Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory…
globenewswire.com Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic,…
globenewswire.com Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to…
globenewswire.com Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Is Allakos Stock Plunging On Monday? On Monday, Allakos Inc (NASDAQ: ALLK) revealed topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU), a skin disorder.
globenewswire.com Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring – AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host…
prnewswire.com Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their…
zacks.com All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
seekingalpha.com Allakos Runs Up Into A Near-Term Catalyst Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006…
globenewswire.com Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
globenewswire.com Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers – Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile ––…
globenewswire.com Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and…
accesswire.com The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc.…
globenewswire.com Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile – AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor…
accesswire.com The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc.…
accesswire.com The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Join LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc.…
accesswire.com The Schall Law Firm Starts Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc.…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 - benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Monday's session saw 175 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 283 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 210 companies reached new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
- benzinga.com Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 - benzinga.com Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
- benzinga.com Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday Gainers
- benzinga.com Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session Gainers
benzinga.com Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday Gainers- benzinga.com Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
- benzinga.com 89 Biggest Movers From Friday Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 215 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 540 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 435 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 236 companies hit new 52-week lows.